Richard Vanbuskirk
Low Vision Rehabilitation · Jackson, CANPI 1316917479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 37.1% of the total. Reporting peaked in 2019 at $119 and has fallen 87.1% since, to $15 in 2025. That places this record below the midpoint for low vision rehabilitation clinicians in CA, where the typical reported total is $402.
Across 10 payments — averaging $32.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$119
- Johnson & Johnson Vision Care, Inc.$103
- Alcon$61
- Coopervision Inc.$20
- Dompe US, Inc.$19
What the payments were for
- Food & beverage$321100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 1 | $119 |
| Johnson & Johnson Vision Care, Inc. | 3 | $103 |
| Alcon | 4 | $61 |
| Coopervision Inc. | 1 | $20 |
| Dompe US, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$119
How this compares
$321 in reported general payments places this provider in the 40th percentile of 37 low vision rehabilitation providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 26 | $49,158 |
| XiidraLifitegrast | 21 | $27,073 |
| RestasisCyclosporine | 15 | $12,437 |
| LumiganBimatoprost | 20 | $10,272 |
| Cyclosporine | 31 | $9,116 |
| Prednisolone Acetate | 129 | $5,816 |
| Travoprost | 25 | $3,598 |
| Loteprednol Etabonate | 16 | $3,551 |
| Latanoprost | 329 | $2,501 |
| Timolol Maleate | 132 | $684 |
| Bimatoprost | 11 | $548 |
| Brimonidine Tartrate | 61 | $389 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $312 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $254 |
| Acyclovir | 14 | $168 |
Paid to pharmacies, not to this prescriber.
Other low vision rehabilitation in Jackson
- Lyly UngSan Francisco$9K
- Joseph LayaRedding$2K
- Shirley HongRowland Heights$2K
- Andrew PhillipsArcadia$1K
- Linda YeeSan Jose$1K
- Grace JengOakland$1K
- Tiffany ChanSan Francisco$1K
- Andy ChenLong Beach$1K
- David ShinFontana$1K
- Leangsok TeaWestminster$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.